IDEAYA Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IDYA Nasdaq 2836 www.ideayabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for IDEAYA Biosciences, Inc.

The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership - Aug 5th, 2026 2:12 pm
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update - Aug 4th, 2026 4:00 am
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Jul 31st, 2026 4:00 am
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers - Jul 27th, 2026 4:00 am
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs - Jul 17th, 2026 7:00 am
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors - Jun 17th, 2026 4:00 am
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers - Jun 15th, 2026 4:00 am
Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study - Jun 11th, 2026 4:20 am
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Jun 10th, 2026 2:05 pm
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results - Jun 9th, 2026 7:29 am
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Inflation Data - Jun 9th, 2026 7:04 am
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants - Jun 8th, 2026 8:22 pm
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Jun 8th, 2026 2:01 pm
What IDEAYA Biosciences (IDYA)'s Darovasertib Phase 2/3 Win and Roche Deal Mean For Shareholders - Jun 6th, 2026 4:08 am
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer - Jun 3rd, 2026 4:00 am
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO - Jun 1st, 2026 9:00 am
IDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology Summit - May 26th, 2026 5:03 pm
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference - May 26th, 2026 4:00 am
IDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA Filing - May 25th, 2026 5:07 am
IDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial Data - May 17th, 2026 10:05 pm